company background image

Janux Therapeutics NasdaqGM:JANX Stock Report

Last Price


Market Cap







01 Oct, 2022


Company Financials +
JANX fundamental analysis
Snowflake Score
Future Growth1/6
Past Performance0/6
Financial Health6/6

JANX Stock Overview

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer.

Janux Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Janux Therapeutics
Historical stock prices
Current Share PriceUS$13.54
52 Week HighUS$29.51
52 Week LowUS$9.39
1 Month Change21.87%
3 Month Change14.75%
1 Year Change-39.45%
3 Year Changen/a
5 Year Changen/a
Change since IPO-46.16%

Recent News & Updates

Aug 09

Janux Therapeutics GAAP EPS of -$0.41, revenue of $2.37M

Janux Therapeutics press release (NASDAQ:JANX): Q2 GAAP EPS of -$0.41. Collaboration Revenue of $2.37M. The company had $354.3 million in cash and cash equivalents and short-term investments at end of second quarter 2022

Shareholder Returns

JANXUS BiotechsUS Market

Return vs Industry: JANX underperformed the US Biotechs industry which returned -25.6% over the past year.

Return vs Market: JANX underperformed the US Market which returned -23.2% over the past year.

Price Volatility

Is JANX's price volatile compared to industry and market?
JANX volatility
JANX Average Weekly Movement12.6%
Biotechs Industry Average Movement11.1%
Market Average Movement6.9%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market2.8%

Stable Share Price: JANX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: JANX's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

201749David Campbell

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company’s lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells.

Janux Therapeutics Fundamentals Summary

How do Janux Therapeutics's earnings and revenue compare to its market cap?
JANX fundamental statistics
Market CapUS$561.93m
Earnings (TTM)-US$54.48m
Revenue (TTM)US$6.73m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
JANX income statement (TTM)
Cost of RevenueUS$43.85m
Gross Profit-US$37.12m
Other ExpensesUS$17.36m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date


Earnings per share (EPS)-1.31
Gross Margin-551.58%
Net Profit Margin-809.63%
Debt/Equity Ratio0%

How did JANX perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.


Is JANX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 2/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for JANX?

Other financial metrics that can be useful for relative valuation.

JANX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue34.3x
Enterprise Value/EBITDA-4.2x
PEG Ration/a

Price to Book Ratio vs Peers

How does JANX's PB Ratio compare to its peers?

JANX PB Ratio vs Peers
The above table shows the PB ratio for JANX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average3.4x
TSVT 2seventy bio
STOK Stoke Therapeutics
KNTE Kinnate Biopharma
GTHX G1 Therapeutics
JANX Janux Therapeutics

Price-To-Book vs Peers: JANX is good value based on its Price-To-Book Ratio (1.6x) compared to the peer average (3.4x).

Price to Earnings Ratio vs Industry

How does JANX's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Book vs Industry: JANX is expensive based on its Price-To-Book Ratio (1.6x) compared to the US Biotechs industry average (1.6x)

Price to Book Ratio vs Fair Ratio

What is JANX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

JANX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate JANX's Price-To-Book Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of JANX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate JANX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate JANX's fair value for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Future Growth

How is Janux Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

Future Growth Score


Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: JANX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: JANX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: JANX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: JANX's revenue (18.5% per year) is forecast to grow faster than the US market (7.7% per year).

High Growth Revenue: JANX's revenue (18.5% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if JANX's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Past Performance

How has Janux Therapeutics performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Last years earnings growth

Earnings and Revenue History

Quality Earnings: JANX is currently unprofitable.

Growing Profit Margin: JANX is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if JANX's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare JANX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: JANX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).

Return on Equity

High ROE: JANX has a negative Return on Equity (-15.85%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Janux Therapeutics's financial position?

Financial Health Score


Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: JANX's short term assets ($358.1M) exceed its short term liabilities ($13.0M).

Long Term Liabilities: JANX's short term assets ($358.1M) exceed its long term liabilities ($28.6M).

Debt to Equity History and Analysis

Debt Level: JANX is debt free.

Reducing Debt: JANX had no debt 5 years ago.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: JANX has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: JANX has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 102.7% each year

Discover healthy companies


What is Janux Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Janux Therapeutics Dividend Yield vs Market
How does Janux Therapeutics dividend yield compare to the market?
SegmentDividend Yield
Company (Janux Therapeutics)n/a
Market Bottom 25% (US)1.7%
Market Top 25% (US)4.7%
Industry Average (Biotechs)2.8%
Analyst forecast in 3 Years (Janux Therapeutics)0%

Notable Dividend: Unable to evaluate JANX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate JANX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if JANX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if JANX's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as JANX has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


David Campbell (62 yo)





Dr. David Campbell, Ph D serves as President, Chief Executive Officer and Director of Janux Therapeutics, Inc. since inception in June 2017. He founded Janux in 2017 to develop tumor-specific cancer therap...

CEO Compensation Analysis

David Campbell's Compensation vs Janux Therapeutics Earnings
How has David Campbell's remuneration changed compared to Janux Therapeutics's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a


Mar 31 2022n/an/a


Dec 31 2021US$8mUS$459k


Sep 30 2021n/an/a


Jun 30 2021n/an/a


Mar 31 2021n/an/a


Dec 31 2020US$812kUS$405k


Compensation vs Market: David's total compensation ($USD8.41M) is above average for companies of similar size in the US market ($USD2.94M).

Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: JANX's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.

Board Members

Experienced Board: JANX's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

NasdaqGM:JANX Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
29 Dec 21SellUS$820,120OrbiMed Advisors LLCCompany40,400US$20.30
21 Dec 21SellUS$2,268,600OrbiMed Advisors LLCCompany119,400US$19.00
16 Dec 21SellUS$7,500,231OrbiMed Advisors LLCCompany393,300US$19.07

Ownership Breakdown

What is the ownership structure of JANX?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders4,519,99910.1%
VC/PE Firms22,910,23451.0%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 106.7% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
Avalon Ventures, LLC
RA Capital Management, L.P.
Klaus Dorner
3,690,427$50.0m0%no data
OrbiMed Advisors LLC
Correlation Ventures, L.P.
Janus Henderson Group plc
Citadel Advisors LLC
BVF Partners L.P.
EcoR1 Capital, LLC
BlackRock, Inc.
1,208,354$16.4m4.01%no data
The Vanguard Group, Inc.
649,640$8.8m14.78%no data
5AM Venture Management, LLC
Adage Capital Management, L.P.
Samsara BioCapital LLC
David Campbell
332,054$4.5m0%no data
Woodline Partners LP
Geode Capital Management, LLC
283,620$3.8m3.05%no data
State Street Global Advisors, Inc.
264,022$3.6m9.1%no data
Tighe Reardon
172,935$2.3m0%no data
Cerity Partners LLC
Northern Trust Global Investments
133,157$1.8m-5.06%no data
Sheila Gujrathi
105,042$1.4m0%no data
Stefan Heller
96,075$1.3m0%no data
JPMorgan Chase & Co, Brokerage and Securities Investments
93,009$1.3m1796.21%no data

Company Information

Janux Therapeutics, Inc.'s employee growth, exchange listings and data sources

Key Information

  • Name: Janux Therapeutics, Inc.
  • Ticker: JANX
  • Exchange: NasdaqGM
  • Founded: 2017
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$561.927m
  • Shares outstanding: 41.50m
  • Website:

Number of Employees


  • Janux Therapeutics, Inc.
  • 11099 North Torrey Pines Road
  • Suite 290
  • La Jolla
  • California
  • 92037
  • United States


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
JANXNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDJun 2021

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/01 00:00
End of Day Share Price2022/09/30 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.